Celldex Therapeutics, Inc.

CLDXSEC EDGAR

In Vitro & In Vivo Diagnostic Substances(DE)CIK: 744218

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Revenue from Contract with Customer, Excluding Assessed Tax	$6.9M	$2.4M	$4.7M	$7.4M	$3.6M
Cost of Goods and Services Sold	$300.0K	$100.0K	$100.0K	$200.0K	$100.0K
Research and Development Expense	$118.0M	$82.3M	$53.3M	$42.5M	$42.7M
Operating Income (Loss)	-$154.5M	-$115.2M	-$71.2M	-$63.4M	-$55.0M
Interest Expense	—	—	—	—	—
Nonoperating Income (Expense)	—	—	—	—	—
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest	-$141.4M	-$112.3M	-$70.7M

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Assets	$792.3M	$465.6M	$352.7M	$444.7M	$235.8M
Assets, Current	$747.2M	$431.7M	$317.7M	$410.8M	$197.8M
Cash and Cash Equivalents, at Carrying Value	$28.4M	$34.8M	$29.4M	$39.1M	$43.8M
Liabilities	$45.3M	$36.5M	$26.5M	$25.2M	$26.5M
Liabilities, Current	$39.5M	$31.1M	$18.6M	$16.5M	$14.2M
Accounts Payable, Current	$3.3M	$3.5M	$3.3M	$1.2M	$1.0M
Stockholders' Equity Attributable to Parent	$326.2M	$419.5M	$209.4M	$94.0M

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Net Cash Provided by (Used in) Operating Activities	-$107.3M	-$103.7M	-$60.9M	-$40.4M	-$46.4M
Net Cash Provided by (Used in) Investing Activities	-$105.8M	$89.9M	-$216.2M	-$98.2M	$17.1M
Net Cash Provided by (Used in) Financing Activities	$218.5M	$4.1M	$272.4M	$171.2M	$16.3M
Payments to Acquire Property, Plant, and Equipment	$1.8M	$1.8M	$1.2M	$1.6M	$731.0K

Access SEC EDGAR data via REST API. Free tier available.

from sec_edgar import SecEdgar

api = SecEdgar("YOUR_KEY")
api.revenue("AAPL", limit=5)